RxDoctor Payments Data

William Bradway, DO

Pulmonary Disease · Cape May Court House, NJNPI 1740224633

Payments from drug & device makers

$1,232in general payments, 2019–2025

Across 65 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$310
  • Sanofi$220
  • Harmony Biosciences LLC$182
  • Philips North America LLC$180
  • Electromed, Inc.$105
  • Inspire Medical Systems, Inc.$98
  • plus $137 from 8 others

What the payments were for

  • Food & beverage$1,06286%
  • Education$17014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,232 in reported general payments places this provider in the 40th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$183,321
Medicare patients
815
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter290$282,194
Breo ElliptaFluticasone/Vilanterol240$128,749
XolairOmalizumab28$116,976
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr105$57,450
Incruse ElliptaUmeclidinium Bromide59$26,320
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$25,534
Fluticasone-SalmeterolFluticasone Propion/Salmeterol142$18,905
Advair HfaFluticasone Propion/Salmeterol37$18,357
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$17,738
Albuterol Sulfate HfaAlbuterol Sulfate484$16,222
SymbicortBudesonide/Formoterol Fumarate53$15,139
Spiriva RespimatTiotropium Bromide15$13,660
Arnuity ElliptaFluticasone Furoate58$13,188
Atrovent HfaIpratropium Bromide19$9,906
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$8,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$310$507,900752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Cape May Court House

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →